Author

Britta Siegmund

New vision of remission: Aiming for mucosal healing in Crohn’s disease through IL-23 inhibition (AbbVie)
New vision of remission: Aiming for mucosal healing in Crohn’s disease through IL-23 inhibition (AbbVie)

Britta Siegmund  et al.

Mesentery as a key player in Crohn's
Mesentery as a key player in Crohn's

Britta Siegmund

Summary: Optimise the use of drugs in IBD
Summary: Optimise the use of drugs in IBD

Britta Siegmund

Phenotypic, genetic and immunologic disease classification: More than CD and CU
Phenotypic, genetic and immunologic disease classification: More than CD and CU

Britta Siegmund

The role of host immunity in triggering chronic intestinal disorders
The role of host immunity in triggering chronic intestinal disorders

Britta Siegmund

THE EFFECT OF MIRIKIZUMAB ON FECAL CALPROTECTIN AND C-REACTIVE PROTEIN IN PHASE 3 STUDIES OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
THE EFFECT OF MIRIKIZUMAB ON FECAL CALPROTECTIN AND C-REACTIVE PROTEIN IN PHASE 3 STUDIES OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Britta Siegmund  et al.

OZANIMOD AS A MAINTENANCE THERAPY IN ADVANCED THERAPY–NAIVE ULCERATIVE COLITIS PATIENTS WITH MODERATE VS SEVERE ENDOSCOPIC DISEASE
OZANIMOD AS A MAINTENANCE THERAPY IN ADVANCED THERAPY–NAIVE ULCERATIVE COLITIS PATIENTS WITH MODERATE VS SEVERE ENDOSCOPIC DISEASE

Britta Siegmund  et al.

THE EFFECT OF MIRIKIZUMAB ON FECAL CALPROTECTIN AND C-REACTIVE PROTEIN IN PHASE 3 STUDIES OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
THE EFFECT OF MIRIKIZUMAB ON FECAL CALPROTECTIN AND C-REACTIVE PROTEIN IN PHASE 3 STUDIES OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Early disease control in UC and CD
Early disease control in UC and CD

Britta Siegmund  et al.

Luminal CD / Luminal CD: Assess, treat, repeat
Luminal CD / Luminal CD: Assess, treat, repeat

Britta Siegmund  et al.

Personalised therapy of IBD: Already clinical practice?
Personalised therapy of IBD: Already clinical practice?

Britta Siegmund

Targeted oral therapies for the treatment of moderate to severe UC (Bristol Myers Squibb)
Targeted oral therapies for the treatment of moderate to severe UC (Bristol Myers Squibb)

Britta Siegmund  et al.

DEVELOPMENT OF A CORE OUTCOME SET FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE THROUGH AN INTERNATIONAL MULTI-STAKEHOLDER DELPHI EXERCISE
DEVELOPMENT OF A CORE OUTCOME SET FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE THROUGH AN INTERNATIONAL MULTI-STAKEHOLDER DELPHI EXERCISE

Britta Siegmund  et al.

TARGET ENGAGEMENT AND PHARMACODYNAMIC MOLECULAR MECHANISM EVALUATION IN A PHASE 1B STUDY OF THE NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN, LEUCINE RICH REPEAT CONTAINING X1 (NLRX1) AGONIST NX-13 IN ULCERATIVE COLITIS
TARGET ENGAGEMENT AND PHARMACODYNAMIC MOLECULAR MECHANISM EVALUATION IN A PHASE 1B STUDY OF THE NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN, LEUCINE RICH REPEAT CONTAINING X1 (NLRX1) AGONIST NX-13 IN ULCERATIVE COLITIS

Britta Siegmund  et al.

DURABILITY OF OZANIMOD RESPONSE BY BASELINE ENDOSCOPIC DISEASE ACTIVITY IN ADVANCED THERAPY–NAIVE PATIENTS WITH ULCERATIVE COLITIS UNCONTROLLED ON CONVENTIONAL THERAPIES: INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION
DURABILITY OF OZANIMOD RESPONSE BY BASELINE ENDOSCOPIC DISEASE ACTIVITY IN ADVANCED THERAPY–NAIVE PATIENTS WITH ULCERATIVE COLITIS UNCONTROLLED ON CONVENTIONAL THERAPIES: INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION

Britta Siegmund  et al.

EFFICACY OF OZANIMOD AS AN INDUCTION THERAPY IN ADVANCED THERAPY–NAIVE ULCERATIVE COLITIS PATIENTS SUBOPTIMALLY CONTROLLED ON CONVENTIONAL TREATMENTS
EFFICACY OF OZANIMOD AS AN INDUCTION THERAPY IN ADVANCED THERAPY–NAIVE ULCERATIVE COLITIS PATIENTS SUBOPTIMALLY CONTROLLED ON CONVENTIONAL TREATMENTS

Britta Siegmund  et al.

EFFECT OF RISANKIZUMAB TREATMENT ON EXTRAINTESTINAL MANIFESTATIONS (EIMS) IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE (CD): RESULTS FROM THE ADVANCE, MOTIVATE AND FORTIFY STUDIES
EFFECT OF RISANKIZUMAB TREATMENT ON EXTRAINTESTINAL MANIFESTATIONS (EIMS) IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE (CD): RESULTS FROM THE ADVANCE, MOTIVATE AND FORTIFY STUDIES

Britta Siegmund  et al.

EPITHELIAL BARRIER FUNCTION SECONDARY TO MICROORGANISMS-INDUCED POLARITY DEFECTS – MECHANISM IN CELIAC DISEASE INITIATION?
EPITHELIAL BARRIER FUNCTION SECONDARY TO MICROORGANISMS-INDUCED POLARITY DEFECTS – MECHANISM IN CELIAC DISEASE INITIATION?

Britta Siegmund  et al.

FATIGUE IMPROVEMENT CORRELATES WITH REDUCTIONS IN WORK PRODUCTIVITY IMPAIRMENT AND RELATED INDIRECT COST IN PATIENTS WITH CROHN’S DISEASE: POST HOC ANALYSIS OF PHASE 3 RISANKIZUMAB INDUCTION TRIALS
FATIGUE IMPROVEMENT CORRELATES WITH REDUCTIONS IN WORK PRODUCTIVITY IMPAIRMENT AND RELATED INDIRECT COST IN PATIENTS WITH CROHN’S DISEASE: POST HOC ANALYSIS OF PHASE 3 RISANKIZUMAB INDUCTION TRIALS

Britta Siegmund  et al.

THE ASSOCIATION OF ENDOSCOPIC AND HISTOLOGIC ENDPOINTS WITH FAECAL CALPROTECTIN AND C-REACTIVE PROTEIN IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB
THE ASSOCIATION OF ENDOSCOPIC AND HISTOLOGIC ENDPOINTS WITH FAECAL CALPROTECTIN AND C-REACTIVE PROTEIN IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB

Britta Siegmund  et al.

Item 1 - 20 / 26
1
2